- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cadila forced to shut Ahemdabad formulations unit after 26 workers test positive
The plant was ordered to be shut down on Thursday, 95 employees had been quarantined and sanitization work at the site had begun.
Ahemdabad: Cadila Pharmaceuticals, one of the largest privately held pharma companies in the country, shut down its formulations manufacturing plant in Ahmedabad on Thursday after more than two dozen of its employees tested positive for the new coronavirus.
A senior government official said late on Thursday that five employees had tested positive for COVID-19 six days back, while 21 others tested positive this week.
"We had collected samples of 30 employees of Cadila on May 5, and 21 of the samples returned positive a day later," said Arun Mahesh Babu, the District Development Officer of Ahmedabad.
He added the plant was ordered to be shut down on Thursday, 95 employees had been quarantined and sanitization work at the site had begun.
The incident comes just days after India began to ease some of its lockdown restrictions aimed at preventing the spread of the new coronavirus. Ahmedabad, however, is one of the more badly affected cities in India and has moved to tighten restrictions this week.
In a statement, Cadila Pharmaceuticals said, "Recently, 26 of our employees from our Dholka manufacturing facility tested positive for COVID-19. Following this, we have closed our operations on our own."
The company also said it is cooperating with the local administration to ensure the safety and security of its facility and surroundings.
Besides Dholka, Cadila Pharmaceuticals has manufacturing facilities in other parts of India and in Ethiopia. The company is a major producer of active pharmaceutical ingredients (API) - the key ingredients used in making a drug.
Read also: Zydus Cadila gets USFDA final nod for Deferasirox Tablets for Oral Suspension
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751